CoChat

Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial

Open access
Plasse, Terry F., Barton, Gary, Davidson, Evelyne, Abramson, Danielle, Kalfus, Ira, Fathi, Reza, Raday, Gilead, Harris, M. Scott · 2020 · American Journal of Gastroenterology

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Previous, small studies have suggested that ondansetron has beneficial effects in diarrhea-predominant irritable bowel syndrome (IBS-D). This randomized, double-blind study evaluated the efficacy and safety of daily 12 mg RHB-102, an investigational bimodal release ondansetron tablet, in IBS-D. METHODS: Men and women with IBS-D by the Rome III criteria, Bristol Stool Scale ≥6 on 2 or more days weekly, and average daily worst pain intensity ≥3/10 were randomized 60:40 to RHB-102 or placebo once daily for 8 weeks. The primary end point was overall stool consistency response for at least 4 of 8 weeks. Secondary end points included overall worst abdominal pain and overall composite response, defined as response on both abdominal pain and stool consistency end points. RESULTS: Overall stool consistency response rates were 56.0% and 35.3% (RHB-102 vs placebo, P = 0.036) and similar among male and female patients. Overall pain response (50.7% vs 39.2%) and composite response rates (40.0% vs 25.5%) favored RHB-102, although these differences were not statistically significant. Stool consistency response rates were enhanced in patients with baseline C-reactive protein above the median (2.09 mg/L), 59.5%, vs 23.1% ( P = 0.009). Overall rates of adverse events were similar, with a higher rate of constipation in RHB-102 patients (13.3% vs 3.9%) that resolved rapidly on withholding treatment. DISCUSSION: RHB-102 was effective and safe in the treatment of men and women with IBS-D. Baseline C-reactive protein seemed to be predictive of response.

Overview

Integrity signals

Registry

Crossref · 10.14309/ajg.0000000000000727

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 1

  1. Sayegh, 2015, Comparative bioavailability study of RHB-102 (24 mg ER tablets QD) versus ondansetron 8 mg trablets BID and a single dose of ondansetron 24 mg in healthy volunteers, Clin Pharm Ther, 97, S47

Cited by

See all 40

Metadata

Authors
Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S.
Affiliations
  • RedHill Biopharma, Tel Aviv, Israel;
  • Arkansas Gastroenterology, PA, North Little Rock Arkansas, USA;
  • New Phase Research & Development, Knoxville, Tennessee, USA;
  • Middleburg Consultants, Takoma Park, Maryland, USA.
Corresponding author
Plasse, Terry F.
Venue
American Journal of Gastroenterology
Published
2020-06-24
Volume
115
Issue
9
Pages
1466-1473
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
OpenAlex
W3041749458
Cited by
40
References
17
Citations by year
2025: 8 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 4
FWCI
5.24
Type
journal article
Language
en
Open access
Locations
  • The American Journal of Gastroenterology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
ondansetron, diarrhea-predominant irritable bowel syndrome, stool consistency, abdominal pain, C-reactive protein, treatment response prediction
MeSH terms
Adolescent, Adult, Aged, Defecation, Diarrhea, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Abdominal Pain, Treatment Outcome, Ondansetron, Irritable Bowel Syndrome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. https://app.cochat.ai/papers/10.14309/ajg.0000000000000727
The paper
Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S. (2020). Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.